Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

Mise à jour : Il y a 4 ans
Référence : NCT00261833

Femme et Homme

Extrait

This is a randomized, placebo-controlled, double-blind, multicenter phase III/IV study to compare the efficacy and safety of Zemaira® with placebo in subjects with emphysema due to alpha1-proteinase inhibitor deficiency. The effect of Zemaira® on the progression of emphysema will be assessed by the decline of lung density, measured by computed tomography (CT).


Critère d'inclusion

  • Alpha1-proteinase Inhibitor Deficiency ,Emphysema


Liens